Key market opportunities for GLP-1 analogues include growth in the oral administration segment, expanding presence in Asia-Pacific and emerging markets, and strategic partnerships. Regulatory ...
New weight-loss drugs in the works will offer more choices beyond GLP-1 options Wegovy and Zepbound. What to know about ...
GLP-1 weight-loss drugs are in the news because so many people are using them to treat obesity and diabetes. With so many ...
Accepting the toxicity data submitted by Macleods Pharmaceuticals, the Subject Expert Committee (SEC) functioning under the ...
Millions of people are now using weight-loss drugs, but it seems there are side-effects that come with the slimmer waistlines ...
Q2 was a strong quarter. Today we shared positive top line data from the ATTAIN-1 orforglipron trial in people with obesity.
From precision‑fermented proteins to GLP‑1 support shots, MISTA’s Growth Hack reveals six breakthrough prototypes shaping the ...
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Epidemiological evidence indicates that MASLD is associated with an ...
A significant portion of modern endocrine research involves Growth Hormone Secretagogues (GHS). These peptides are designed ...
Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 202 ...
Assistant Controller of Patents (C.A. (COMM.IPD-PAT) 76/2022), the Delhi High Court upheld the refusal of a patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results